Zura Bio Limited
NASDAQ:ZURABiotechnology
Healthcare
$0.97 +1.93%
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
52W Low $1.00High $7.44
Volume 3.02M
Average 0.75M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$64.81M
FY 2025 · Annual
Investing Cash Flow
-$113,000.00
FY 2025 · Annual
Financing Cash Flow
-$2.16M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 8.42M | (27.33M) | (60.56M) | (52.4M) | (68.65M) |
| Depreciation & Amortization | 0 | 0 | 0 | 9K | 49K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 334K | 9.66M | 16.8M | 12.33M |
| Change in Working Capital | (235.6K) | 3.54M | 5.12M | 2.31M | (3.63M) |
| Accounts Receivables | 2.87K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 288.29K | 0 | 4.21M | (2.16M) |
| Other Working Capital | (238.47K) | 3.25M | 5.12M | (1.91M) | (1.47M) |
| Other Non-Cash Items | (9.28M) | 22.26M | 30.74M | 5.21M | (4.91M) |
| Operating Cash Flow | (1.1M) | (1.2M) | (15.05M) | (28.08M) | (64.82M) |
| Capital Expenditures | (4) | (12M) | (8M) | (75K) | (113K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (139.38M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (5M) | 0 |
| Investing Cash Flow | (139.38M) | (12M) | (8M) | (5.08M) | (113K) |
| Debt Repayment | (117.38K) | 7.6M | (10M) | 0 | 0 |
| Common Stock Issued | 140.82M | 0 | 116.41M | 60.76M | 5.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 505K | (2.83M) | 14.89M | 49.09M | (7.37M) |
| Financing Cash Flow | 141.21M | 14.77M | 121.29M | 109.84M | (2.16M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 729.22K | 1.57M | 98.24M | 76.69M | (67.09M) |
| Free Cash Flow | (1.1M) | (13.2M) | (23.05M) | (28.15M) | (64.93M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$68.7M
+ D&A$49.0K
+ Stock-Based Comp$12.3M
+ Deferred Tax$0
- Working Capital-$3.6M
- Other Non-Cash-$4.9M
= Operating Cash Flow-$64.8M
- Capex-$113.0K
= Free Cash Flow-$64.9M
Analysis
FY2025 free cash flow is -$64.9M. FCF conversion is 94.6% of net income. Operating cash flow was -$64.8M, with capex of -$113.0K. The largest bridge item is Stock-Based Comp at $12.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| EFFECT | EFFECT filing | Nov 3, 2026 | |
| S-3 | S-3 filing | Oct 27, 2026 | |
| 8-K | Current report | Oct 27, 2026 | |
| 10-Q | Quarterly report | Oct 27, 2026 |
Does ZURA generate free cash flow?
Zura Bio Limited (ZURA) generated -$64.93M of free cash flow in fiscal 2025.
How much operating cash flow does ZURA produce?
Operating cash flow was -$64.81M, before capital expenditures of $113,000.00.
Continue the stock analysis
Jump to another research area for this company.